Estrogen Metabolism After 35: Why You Feel Different and What Your Body Actually Needs

Rachel is 38. She used to wake up feeling clear, energized, and ready. Now she drags herself out of bed after another night of broken sleep. She was up at 3am again. No reason. Just wide awake, staring at the ceiling.

By mid-morning, she is bloated. Her jeans feel tight even though she has not changed how she eats. Her mood shifts without warning. One minute she is fine. The next, she is snapping at her kids over something that would not have bothered her a year ago. Her periods have gotten heavier and more painful. She has gained weight around her midsection that will not budge no matter how much she exercises.

She brought it up at her last appointment. Her doctor ran standard bloodwork. Everything came back within normal range. She left more frustrated than when she walked in.

Frustrated but not willing to accept "everything looks fine," Rachel found a practitioner who ordered an estrogen fractionation test. This panel measures the three main estrogens individually: E1 (estrone), E2 (estradiol), and E3 (estriol). It also evaluates estrogen metabolites to show how efficiently her body is processing and clearing them.

The results told a different story than her standard labs. Her total estrogen was elevated. Her E1 (estrone) was high, which is common when estrogen is not being cleared efficiently and recirculates. Her E2 (estradiol) was above the optimal range for her cycle phase. Her ratio of 2-hydroxyestrone to 16α-hydroxyestrone was low, meaning estrogen was being pushed toward less favorable metabolic pathways. And her 4-hydroxyestrone, a reactive metabolite associated with oxidative stress, was elevated (5, 8).

Now Rachel had data that matched what her body had been telling her for months. Her estrogen levels were not just high. Her body was struggling to break estrogen down through the right pathways and move it out. The standard panel never looked at any of this.

Rachel is not imagining this. She is not lazy. She is not "just stressed." Her biochemistry has shifted. And without evaluating how efficiently her body metabolizes estrogen, no standard lab panel was going to catch it.

What Is Estrogen Metabolism and Why Does It Matter After 35?

Estrogen is essential. It supports mood, energy, cognitive function, bone density, and reproductive health (1). It is not the enemy. The problem starts when your body's ability to break down and clear estrogen begins to slow.

As women move through their mid-thirties and into their forties, hormone levels naturally fluctuate. But the issue is not just how much estrogen you have. It is how well your body processes it (2).

When estrogen metabolism is running efficiently, your liver breaks estrogen down, packages it for elimination, and your gut escorts it out of the body. When that process slows, estrogen can recirculate instead of being cleared. That recirculation is when many women start noticing symptoms they cannot explain (3).

How Your Body Processes Estrogen (And Where It Can Slow Down)

Estrogen metabolism happens in three phases. Think of it like a relay race. Each leg depends on the one before it.

Phase I: Liver Breakdown

Your liver converts estrogen into metabolites using CYP enzymes, including CYP1A1, CYP1A2, and CYP1B1. Not all of these metabolites are equal. Some are favorable. Others are reactive and potentially harmful (4). The direction estrogen gets pushed during Phase I matters enormously. Favorable 2-hydroxylation is what we want. When estrogen gets pushed down the 4-hydroxylation pathway via CYP1B1, it produces reactive quinone metabolites that can damage DNA if they are not neutralized (5).

Phase II: Liver Packaging

Your liver then packages those metabolites through conjugation pathways. One of the most important is glucuronidation. This step prepares estrogen metabolites for elimination (6). However, an enzyme called beta-glucuronidase can unwrap that package in the gut. When that happens, estrogen re-enters circulation instead of leaving the body (7).

Methylation also plays a role here. The COMT enzyme methylates certain estrogen metabolites to prepare them for elimination. If methylation is sluggish due to MTHFR variants or nutrient deficiencies, this pathway slows down and reactive estrogen metabolites can accumulate (8).

Phase III: Gut Elimination

This is the final leg. Your gut is responsible for escorting packaged estrogen out of the body. If gut health is compromised or beta-glucuronidase activity is elevated, this step stalls. Estrogen recirculates. The load increases (9).

On top of all this, your body is also producing estrogen through aromatase enzyme activity, which converts androgens into estrogen (10). Your liver is simultaneously processing environmental compounds that mimic estrogen from plastics, pesticides, parabens, and synthetic fragrances (11). Genetic variants in genes like COMT, CYP1B1, and UGT can further influence how efficiently each of these phases runs (12). Some women's bodies are simply working harder to clear estrogen than others.

Signs Your Estrogen Metabolism May Need Support

Many women in their late thirties through fifties experience shifts they never connect to estrogen metabolism. The following are some of the most common signs, listed in order of how frequently they are reported in clinical and research settings. These signs may also overlap with other hormonal or health conditions, so working with a qualified healthcare provider is important for proper evaluation.

• Heavier or more painful periods. Estrogen supports the growth of the uterine lining. When estrogen levels are higher than optimal relative to progesterone, the lining can build up excessively, leading to heavier menstrual flow and increased discomfort (24). This is one of the most commonly reported signs in women with suboptimal estrogen metabolism.
• Breast tenderness or fullness before menstruation. Estrogen stimulates breast tissue growth. When estrogen is elevated or not being cleared efficiently, breast tenderness and swelling can become more pronounced, particularly in the luteal phase of the cycle (25). Fibrocystic breast changes have also been associated with elevated estrogen levels (26).
• Cyclical bloating, water retention, or puffiness. Estrogen influences fluid balance and can increase water retention when levels are elevated relative to progesterone (27). Many women notice this pattern worsening in the days leading up to menstruation.
• Mood changes such as irritability, weepiness, or a noticeably shorter fuse. Estrogen interacts with serotonin, dopamine, and norepinephrine in the brain. When estrogen and progesterone are out of balance, mood regulation can be disrupted, contributing to irritability, nervousness, and emotional sensitivity (28). These changes are often more pronounced in the premenstrual window.
• Weight changes, particularly around the midsection. Hormonal shifts during the perimenopausal transition are associated with a redistribution of body fat from a gynoid (hips and thighs) to an android (abdominal) pattern (29). Changes in the estrogen to progesterone ratio, combined with alterations in insulin sensitivity, can make midsection weight particularly resistant to diet and exercise (30).
• Sleep disruptions, particularly waking between 2am and 4am. Fluctuations in estrogen and progesterone affect sleep architecture, including the ability to stay asleep. Sleep problems increase two to three and a half times in women during the menopausal transition (31). Progesterone has sleep-promoting properties, and its decline relative to estrogen can contribute to middle-of-the-night waking (32).
• Brain fog, difficulty concentrating, or trouble finding words. Estrogen receptors are concentrated in brain areas involved in memory and executive function, including the hippocampus and prefrontal cortex (33). During perimenopause, women commonly report subjective cognitive difficulties including forgetfulness, reduced processing speed, and difficulty with verbal recall (34). Longitudinal studies confirm small but reliable declines in memory performance during this transition that are not explained by aging alone (35).
• Low energy or fatigue that does not improve with rest. Hormonal imbalances, including elevated estrogen relative to progesterone, can contribute to persistent fatigue. This can be compounded by disrupted sleep, mood changes, and the metabolic burden of processing excess estrogen (36).
• Hormonal headaches or migraines. The drop in estrogen that occurs in the late luteal phase is a well-established trigger for menstrual migraines in susceptible women (37). When estrogen metabolism is inefficient and levels fluctuate more dramatically, the frequency and severity of these headaches may increase.
• Skin changes along the jawline and chin. Hormonal acne in adult women is strongly associated with androgen activity, and the estrogen to androgen ratio plays a role. When estrogen metabolism is sluggish and the balance shifts, it can contribute to increased sebum production and breakouts concentrated along the jawline and lower face (38, 39).
• Hair thinning. Estrogen supports the hair growth cycle. When estrogen metabolism is disrupted and the balance between estrogen and androgens shifts, hair thinning can occur, particularly during perimenopause (40).
• Decreased libido. Although optimal estrogen levels support healthy sexual desire, disruptions in estrogen balance, particularly when combined with mood changes, fatigue, and sleep disruption, can reduce libido (41).
• A general sense of not feeling like yourself. Many women describe this as the overarching experience. It is the cumulative effect of multiple systems being affected by suboptimal estrogen metabolism.

These experiences are common. But common does not mean you have to accept them. Supporting your body's natural estrogen metabolism pathways can make a meaningful difference in how you feel day to day.

Why I Formulated Estrogen Nutrients

Most estrogen support supplements take a single approach. They include DIM, or I3C, or calcium D-glucarate, and call it a day. But healthy estrogen metabolism is not one step. It is a complete process with multiple stages that all need to be running efficiently.

After working with thousands of women navigating these exact challenges, I was tired of recommending five separate supplements and watching people struggle to keep up. That can easily run in excess of $150 or more per month. And even then, you may not have the right forms, the right doses, or the right combination. When a protocol feels overwhelming, most people scale back or stop entirely.

I formulated Estrogen Nutrients to address each of these issues. It supports healthy aromatase activity to address estrogen production. It supports glucuronidation to help move estrogen out through the stool so it is not recirculated. It supports sulfation pathways. And it helps support a healthy response to reactive estrogen metabolites. Production, metabolism, detoxification, elimination, and response. Not just one piece of the puzzle.†

Eight targeted ingredients in two capsules per serving. Designed to support Phase I liver metabolism, Phase II glucuronidation and methylation, gut elimination, healthy aromatase activity, sulfite processing from cruciferous compounds, and healthy response to reactive estrogen metabolites. Production, metabolism, detoxification, elimination, and response in one formula.†

What Is Inside and Why

Calcium D-Glucarate

This is a major detoxification route and most people do not know about it. Calcium D-glucarate supports glucuronidation, one of the key Phase II conjugation pathways in the liver. It helps inhibit beta-glucuronidase, the enzyme that unwraps packaged estrogen in the gut and allows it to recirculate. In a clinical study, calcium D-glucarate administration resulted in longer inhibition of beta-glucuronidase activity compared to other forms (13).†

This is exactly why I included it. You can take all the DIM and I3C you want. But if beta-glucuronidase is elevated, those estrogens are coming right back into circulation. Calcium D-glucarate supports the body's natural excretion process so that Phase I is not working for nothing.†

Indole-3-Carbinol (I3-6™)

I3C provides support beyond what DIM offers on its own. It supports CYP1A1 and CYP1A2 enzyme activity, which promotes favorable 2-hydroxylation of estrogen (14). In a phase I clinical trial, women taking 400 mg of I3C daily experienced a 66% increase in the favorable 2-hydroxyestrone to 16α-hydroxyestrone ratio (15). The I3-6™ form delivers additional metabolites that support broader Phase I activity.†

DIM / Diindolylmethane (Ceti VI™)

DIM supports the liver's processing of estrogen and promotes the formation of favorable estrogen metabolites at the Phase I level (16). Most estrogen supplements stop here. That is why I paired it with I3C for broader Phase I coverage and with calcium D-glucarate, Siliphos, and the other ingredients to support the full process from production through elimination.†

Luteolin Phospholipids

This is where we address estrogen production itself. Luteolin supports healthy aromatase activity (10). Aromatase is the enzyme that converts androgens into estrogen. If aromatase activity is elevated, your body is producing more estrogen than it needs. Most estrogen formulas completely miss this piece. They only address what happens after estrogen is made. They never address how much is being made in the first place.†

I paired luteolin with Siliphos because they work synergistically to support natural estrogen breakdown. The phospholipid delivery form supports absorption so the luteolin can actually get where it needs to go (17).†

Phytosome Milk Thistle Extract (Siliphos®)

Siliphos supports healthy liver function, which is the engine of estrogen metabolism. But I included this specific form for another reason. Silymarin and its components have been shown to support healthy beta-glucuronidase activity (18). That means Siliphos works alongside calcium D-glucarate to keep packaged estrogen moving toward elimination.†

This is a phospholipid-bound form with up to 10x the absorption of standard milk thistle extracts (19). If you are going to include milk thistle, the form matters.†

Broccoli Seed Extract (BroccoRaphanin®)

This is where we support a healthy response to the reactive estrogen metabolites I described in Phase I. When estrogen gets pushed down the 4-hydroxylation pathway via CYP1B1, it produces reactive quinone metabolites. These can form depurinating DNA adducts that damage cellular integrity (5). Sulforaphane, generated from the glucoraphanin in BroccoRaphanin, activates Nrf2 pathways that support neutralization of these reactive metabolites (20).†

BroccoRaphanin includes myrosinase for reliable sulforaphane conversion. This is not a generic broccoli extract. It is a concentrated, standardized source designed to deliver meaningful sulforaphane production in the body.†

Riboflavin (as Riboflavin 5'-Phosphate Sodium)

This is an ingredient most estrogen formulas leave out entirely. Riboflavin is an essential cofactor for the NQO1 enzyme, which helps reduce reactive quinone estrogen metabolites back to less harmful forms (21). If riboflavin is deficient, NQO1 cannot do its job and those reactive metabolites accumulate.†

Riboflavin also supports MTHFR enzyme function. MTHFR is needed for methylation. Methylation feeds the COMT enzyme, which eliminates another category of reactive estrogen metabolites (22). So this one nutrient supports two separate pathways for the body’s natural response to harmful estrogen forms. This is the active, bioavailable 5'-phosphate form. Not the cheaper inactive form found in most multivitamins.†

Molybdenum (as Albion® Glycinate Malate)

I added molybdenum because many people experience gas, bloating, or headaches when they take DIM or cruciferous supplements. These symptoms often indicate that sulfite metabolism needs support. When DIM and I3C are metabolized, sulfur compounds are produced that require the sulfite oxidase (SUOX) enzyme for processing. Molybdenum is the essential mineral cofactor for SUOX (23).†

This one ingredient can make the difference between someone tolerating the formula comfortably or giving up on it. The Albion chelated form is designed for optimal absorption.†

Premium Quality. Simplified Routine.

Estrogen Nutrients features branded, research-backed ingredients including Siliphos®, BroccoRaphanin®, Albion® minerals, I3-6™, and Ceti VI™ in bioavailable forms your body can readily use. No folic acid. No unnecessary fillers. Vegetarian capsules. Two capsules per serving. 30 servings per bottle.†

For women who have been purchasing DIM, calcium D-glucarate, milk thistle, broccoli seed extract, and B vitamins separately, Estrogen Nutrients consolidates an entire estrogen support protocol into a single product. Less cost. Less confusion. Less daily effort.†

Back to Rachel

Rachel started taking Estrogen Nutrients after a meal each day as part of a broader commitment to supporting her hormone health. She also focused on improving her gut health, reducing her exposure to environmental estrogens from plastics and personal care products, and prioritizing sleep.

Within a few weeks, she noticed she was sleeping through the night consistently. She was not experiencing bloating. Her mood felt steady. Her periods were manageable. Mental clarity was supported. She started feeling more like herself.†

Her body was processing and clearing estrogen efficiently. Not because one ingredient fixed everything. But because the full pathway was finally being supported.†

Support Your Body's Natural Estrogen Metabolism

Your body processes estrogen every single day. If that process needs additional nutritional support due to age, genetics, environment, or lifestyle, giving it the right building blocks can make a meaningful difference in your daily wellbeing.†

You do not have to keep guessing with five separate bottles. You do not have to keep pushing through and calling it normal. There is a more comprehensive, more streamlined way to support what your body is already trying to do.†

Shop Estrogen Nutrients →

Take the Hormone Health Quiz →

Read Dr. Ben Lynch's Story Behind the Formula →

†Individual results may vary. These accounts are illustrative and not guarantees of specific outcomes.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Always consult with a qualified healthcare professional before starting any new supplement, especially if you are pregnant, nursing, taking medication, or have a medical condition.

References

1. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013;19(3):197-209.
2. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011;38(3):455-466.
3. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227(2):115-124.
4. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999;20(8):1607-1613.
5. Yang L, Zahid M, Liao Y, et al. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis. 2013;34(11):2587-2592.
6. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003;3(3):136-158.
7. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst. 2016;108(8):djw029.
8. Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer. 2008;122(9):1949-1957.
9. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45-53.
10. Lu DF, Yang LJ, Wang F, Zhang GL. Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19). J Agric Food Chem. 2012;60(34):8411-8418.
11. Gore AC, Chappell VA, Fenton SE, et al. EDC-2: The Endocrine Society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):E1-E150.
12. Lim YC, Li L, Desta Z, et al. Endogenous estrogen metabolism by cytochrome P450 and UDP-glucuronosyltransferases in human liver microsomes. Drug Metab Dispos. 2006;34(4):563-571.
13. Dwivedi C, Heck WJ, Downie AA, et al. Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits. Biochem Med Metab Biol. 1990;43(2):83-92.
14. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005;4(9):1201-1215.
15. Reed GA, Peterson KS, Smith HJ, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1953-1960.
16. Thomson CA, Chow HHS, Wertheim BC, et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 2017;165(1):97-107.
17. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7):634-646.
18. Kim DH, Jin YH, Park JB, Kobashi K. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull. 1994;17(3):443-445.
19. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009;14(3):226-246.
20. Houghton CA, Fassett RG, Coombes JS. Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician's expectation be matched by the reality? Oxid Med Cell Longev. 2016;2016:7857186.
21. Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer. 2008;122(9):1949-1957.
22. Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003;77(6):1352-1360.
23. Abumrad NN, Schneider AJ, Steel D, Rogers LS. Amino acid intolerance during prolonged total parenteral nutrition reversed by molybdate therapy. Am J Clin Nutr. 1981;34(11):2551-2559.
24. Hapangama DK, Bulmer JN. Pathophysiology of heavy menstrual bleeding. Womens Health (Lond). 2016;12(1):3-13.
25. Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol. 1997;177(1):126-132.
26. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.
27. White CP, Hitchcock CL, Vigna YM, Prior JC. Fluid retention over the menstrual cycle: 1-year data from the prospective ovulation cohort. Obstet Gynecol Int. 2011;2011:138451.
28. Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008;33(4):331-343.
29. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429.
30. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32(6):949-958.
31. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause. 2003;10(1):19-28.
32. Morssinkhof MWL, van Wylick DW, Priber S, et al. Associations between sex hormones, sleep problems and depression: a systematic review. Neurosci Biobehav Rev. 2020;118:669-680.
33. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20(3):279-307.
34. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol. 2014;142:90-98.
35. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional's guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578.
36. Dennerstein L, Lehert P, Burger HG, Dudley E. Mood and the menopausal transition. J Nerv Ment Dis. 1999;187(11):685-691.
37. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3(6):354-361.
38. Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41-49.
39. Khunger N, Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol. 2012;78(3):335-341.
40. Mirmirani P. Hormonal changes in menopause: do they contribute to a 'midlife hair crisis' in women? Br J Dermatol. 2011;165 Suppl 3:7-11.
41. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002;77 Suppl 4:S42-48.